论文部分内容阅读
目的评估利巴韦林联合布地奈德交替雾化吸入治疗毛细支气管炎的临床疗效。方法将72例毛细支气管炎患儿随机分为两组,在常规对症治疗的基础上,治疗组38例给予利巴韦林、布地奈德交替雾化吸入,对照组34例给予布地奈德交替雾化吸入,观察治疗后两组患儿咳嗽和喘息的缓解时间、肺部喘鸣音及湿啰音和低氧血症的消失时间、住院天数以及血常规、肝肾功能指标。结果治疗组治疗后患儿咳嗽和喘息的缓解时间、肺部喘鸣音及湿啰音和低氧血症的消失时间和住院时间均短于对照组,差异均有统计学意义(P<0.05)。结论利巴韦林与布地奈德交替雾化吸入改善病情更快,疗效更好,且用药安全,未见明显不良反应,值得临床推广应用。
Objective To evaluate the clinical efficacy of ribavirin combined with budesonide inhalation for the treatment of bronchiolitis. Methods 72 children with bronchiolitis were randomly divided into two groups. On the basis of conventional symptomatic treatment, 38 patients in the treatment group received ribavirin and budesonide were alternately inhaled, while 34 patients in the control group were given budesonide alternating Atomization inhalation was used to observe the relief time of cough and wheeze, the time of pulmonary wheezing, the disappearance of dampness and hypoxemia, days of hospitalization, blood routine and liver and kidney function in both groups after treatment. Results After treatment, the relieving time of cough and wheeze, the disappearance time of lung wheezing, wet rales and hypoxemia and the length of hospital stay in treatment group were shorter than those in control group (P <0.05 ). Conclusion Ribavirin and budesonide alternately inhalation to improve the disease faster and better efficacy, and medication safety, no obvious adverse reactions, it is worth promoting the clinical application.